KR20170082026A - Composition for prevention of hair loss or promotion of hair growth comprising ginsenoside F5 - Google Patents

Abstract

Disclosed herein is a composition for preventing hair loss or promoting hair growth comprising ginsenoside F5. The composition can be used for improving hair loss, treating or preventing hair loss because it promotes placental growth factor secretion of dermal papilla cells and improves the pore depth and scalp thickness.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention of hair loss or promotion of hair growth comprising ginsenoside F5 (Composition for prevention of hair loss or promotion of hair growth comprising ginsenoside F5)

Disclosed herein is a composition for preventing hair loss or promoting hair growth comprising ginsenoside F5.

Hair is an important part of the body that, although not critical to life, is a measure of health and determines appearance from a cosmetic point of view. Therefore, daily hair loss is considered natural physical activity for many people with hair, but people with hair loss due to aging or various other causes are affected by depression, shame, social isolation, etc., .

Although research on the prevention of hair growth, wool and hair loss has been carried out for a long time, the mechanism of hair growth and hair loss has not yet been clarified yet. Recently, many universities and corporate research institutes around the world have been studying cytologic, biochemical Or molecular biology research, and has been making efforts to develop drugs that can treat hair loss and promote hair growth.

Currently, drugs that promote hair growth are approved by the US Food and Drug Administration (FDA) such as Minoxidil, Finasteride and Propecia. However, these drugs have a short duration of effect, have a side effect such as loss of sexual desire, risk of pregnant women, drug abuse, or the like.

KR10-2003-7001736A

In one aspect, an object of the present invention is to provide a composition for preventing or improving hair loss, or for promoting hair growth.

In another aspect, the object of the present invention is to promote secretion of placental growth factors in dermal papilla cells using ginsenoside F5.

In one aspect, the present invention provides a composition for preventing or improving hair loss or promoting hair growth comprising ginsenoside F5 as an active ingredient.

In one aspect, a composition comprising, as an active ingredient, ginsenoside F5, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof, as an active ingredient, , The depth of the pores and the thickness of the scalp can be improved, so that hair loss prevention or hair growth promoting effect can be obtained. In addition, since it is harmless to human body, hair loss can be treated without side effects.

FIG. 1 is a graph showing the expression level of placental growth factor after treatment with ginsenoside F5 (con: control group, EGC: epigallocatechin treated group, EGCG: epigallocatechin gallate treated group, GT stem F1: treated with ginsenoside F1, treated with ginsenoside F2, treated with ginsenoside F5, treated with ginsenoside K treatment group).

The amount of placental growth factor secreted from the dermal papilla cells decreases with the passage of the oocyte. On the other hand, when the placental growth factor (PIGF) is applied to the scalp, the hair shaft, the depth of the pore and the scalp thickness increase to a similar degree as that of minoxidil, which is widely used as a hair growth promoter (Yoon SY et al., Journal of Dermatological Science. 2014). On the other hand, the inventors of the present invention confirmed that the treatment of dermal papilla cells with ginsenoside F5 increased the amount of placental growth factors secreted by the dermal papilla cells, thereby completing the present invention.

Hereinafter, the present invention will be described in detail.

In one aspect, the present invention relates to a composition for preventing or improving hair loss or promoting hair growth comprising ginsenoside F5, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof as an active ingredient to be.

The ginsenoside F5 can be, for example, a material having the following structure:

.

.

As used herein, the term "isomers" refers in particular to optical isomers (for example, essentially pure enantiomers, essentially pure diastereomers or mixtures thereof) as well as morphological isomers (i. e., isomers differing only in the angle of one or more chemical bonds), position isomers (especially tautomers) or geometric isomers (e.g., cis-trans isomers) do.

As used herein, "essentially pure ", when used in reference to an enantiomer or partial isomer, refers to an enantiomer or partial isomer of a specific compound, such as about 90% or more, specifically about 95% More specifically about 97% or more, or about 98% or more, more specifically about 99% or more, still more specifically about 99.5% or more (w / w).

As used herein, the term " pharmaceutically acceptable "refers to the approval of a government or equivalent regulatory agency that can be used on animals, and more specifically on humans, by avoiding significant toxic effects when used in conventional medicinal dosage Received, approved, or listed in pharmacopoeia or other general pharmacopoeia.

As used herein, "pharmaceutically acceptable salt" means a salt according to one aspect of the present invention which is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. The salt may be (1) formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; (4-hydroxybenzoyl) benzoic acid, acetic acid, propionic acid, hexanoic acid, cyclopentenepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4- chlorobenzenesulfonic acid, 2- 4-methylbicyclo [2,2,2] -oct-2-en-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert Acid addition salts formed with organic acids such as butylacetic acid, lauric sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid; Or (2) salts formed when the acidic proton present in the parent compound is substituted.

As used herein, the term " prodrug "refers to a drug that chemically changes a drug to control its physical and chemical properties. Although it does not exhibit physiological activity itself, The drug can be turned into a drug.

As used herein, "hydrate " means a compound to which water is bound, and is a broad concept that includes an inclusion compound having no chemical bonding force between water and the compound.

As used herein, "solvate" means a higher order compound formed between a molecule or ion of a solute and a molecule or ion of a solvent.

In the present specification, "hair loss" may mean that hair is normally absent at the site where hair should be present, and may mean, for example, that the hair of the scalp is missing.

Further, in this specification, "promoting hair growth" may mean promoting the generation of new hair as well as allowing existing hair to grow healthily.

In this aspect, the composition may be one which promotes the secretion of growth factors of scalp cells.

As used herein, " scalp cells " may include all kinds of cells constituting the epidermis, dermis and subcutaneous tissue of the scalp.

In one embodiment, the scalp cell may be human follicle dermal papilla cells. The dermal papilla cells are cells separated from the dermal cell layer and present in the base of the hair follicle. The dermal papilla cells are known to supply oxygen and nutrients to the cells that make up the hair follicles, which are responsible for hair growth and follicle cycle regulation.

In this aspect, the growth factor may be a placental growth factor (PIGF). The placenta growth factor is a protein encoded by the PGF gene, which is a type of vascular endothelial growth factor (VEGF).

In this respect, the ginsenoside F5 may be derived from ginseng. The ginseng may be a root, stem, flower, fruit or leaf part of ginseng. Ginsenoside F5 is especially abundant in water ginseng. For example, ginsenoside F5 can be obtained by extracting water ginseng.

As used herein, "ginseng" may mean perennial plants of the genus Araliaceae and may include leaves, roots, tissue cultures, fruits, and seeds. The height is 50 to 60 cm. The stem is straight out from the short, thick rootstock, and the bottom root is separated from the root by one root, which is divided into several branches. Leaves are five leaf-like leaves arranged in a palm-like shape, and they run on the stems from the rootstock. One-year-old leaves grow one by one, and each leaves five to six years after five to six years of harvest. Three years after the buds have emerged, a pale green flower blooms in April-May, with a mountain-shaped inflorescence on the top of the stem. Calyx leaf, petal and stamen are 5 each, and stigma is divided into 2 branches.

As used herein, the term "extract" includes all substances obtained by extracting the components of a natural product, regardless of the extraction method, extraction solvent, extracted component or extract form, The present invention is a broad concept including all substances that can be obtained by processing or treating in other ways. Specifically, the processing or treatment may be an additional fermentation or enzymatic treatment of the extract. Thus, the extract herein is a broad concept including fermentation products, concentrates, and dried products.

For example, the ginseng extract may be obtained by adding water or alcohol (for example, 3 L) to the dried ginseng product, filtering it at room temperature or refluxing, and then concentrating it under reduced pressure at 40 to 45 ° C. The concentration of the alcohol may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90%. The organic solvent may be an organic solvent having low polarity, for example, hexane, methylene chloride, ethyl acetate, butanol. Thus, the ginseng extract may be a soluble fraction of the organic solvent extracted with the organic solvent having a low polarity.

In one aspect of the present invention, in compositions for preventing or improving hair loss, or for promoting hair growth, the ginsenoside F5 may be included at 0.1 ppm (w / w) to 10% (w / w) have. For example, the ginsenoside F5 may be present in an amount of 0.1 ppm or more, 1 ppm or more, 3 ppm or more, 5 ppm or more, 7 ppm or more, 9 ppm or more, 10 ppm or more, 100 ppm or more, 300 ppm or more, 500 ppm or more, (W / w) or less, more preferably 10 ppm (w / w) or less, more preferably 1000 ppm or more, 3000 ppm or more, 5000 ppm or more, 7000 ppm or more, 9000 ppm or more, 10000 ppm or more, 30000 ppm or more, 50000 ppm or more, w / w, not more than 6% (w / w), not more than 4% (w / w), not more than 2% (w / w), not more than 1% (w / ) Or less, 0.01% (w / w) or less, 0.001% (w / w) or less, or 0.00001% (w / w) or less. 1 to 1000 ppm (w / w), 1 to 100 ppm (w / w), 5 to 50 ppm (w / w), 7 to 20 ppm (w / w, 8 to 15 ppm (w / w), or 8 to 12 ppm (w / w). For example, when ginsenoside F5 is contained in an amount of 1 to 1000 ppm (w / w), hair loss improvement or hair growth promoting effect may be excellent.

In this aspect, the composition may be a pharmaceutical composition. The pharmaceutical composition according to one aspect of the present invention may be various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, soft or hard capsules, etc. These solid preparations may contain one or more excipients such as starch, calcium carbonate, sucrose, Or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.

In one aspect of the invention, the pharmaceutical dosage form of the compositions may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds, as well as in suitable aggregates. The salt is not particularly limited as long as it is pharmaceutically acceptable so long as it is pharmaceutically acceptable and includes, for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, , Benzenesulfonic acid, toluenesulfonic acid, and naphthalenesulfonic acid.

In one aspect of the present invention, the composition may be administered parenterally or orally, as desired, and may be administered in an amount of 0.1 to 500 mg, preferably 1 to 100 mg, per 1 kg of body weight per day, . ≪ / RTI > The dosage for a particular patient may vary depending on the patient's body weight, age, sex, health condition, diet, time of administration, administration method, excretion rate, severity of disease, and the like.

The pharmaceutical composition according to one aspect of the present invention can be administered orally or parenterally in the form of powders, granules, tablets, soft or hard capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, Suppositories, injections, sterile injectable solutions, and the like, and may be formulated in any form suitable for pharmaceutical preparations, preferably in the form of injections or external preparations for skin.

Compositions according to one aspect of the present invention may be administered to mammals such as rats, mice, livestock, humans, and the like by various routes such as parenteral, oral, etc., and all manner of administration may be expected, Oral, transdermally, intravenously, intramuscularly, or subcutaneously.

The composition according to one aspect of the present invention can be administered by various routes that can be easily applied by a person skilled in the art. In particular, the pharmaceutical composition according to one aspect of the present invention can be administered by a route applied to the skin surface as an external preparation for skin.

In addition, the composition may be a cosmetic composition. Specifically, the cosmetic composition may be, for example, a hair cosmetic composition, a body cosmetic composition, a basic cosmetic composition, or a makeup cosmetic composition, and the formulation is not particularly limited and may be appropriately selected according to the purpose.

For example, the cosmetic composition can be formulated into a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, But is not limited thereto. More particularly, the present invention relates to a cosmetic composition for hair such as a cleansing agent such as a shampoo, a rinse, a body cleanser, a hair conditioner such as a hair tonic, a gel or a mousse, a hair conditioner, Basic cosmetics such as massage cream, moisturizing cream, hand cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, gel, patch, oil water (O / W) ≪ / RTI >

The cosmetic composition contains a cosmetically acceptable medium or base. It may be in any form suitable for topical application, for example as a solution, a gel, a solid or a paste anhydrous product, an emulsion obtained by dispersing an oil phase in water, a suspension, a microemulsion, a microcapsule, a microgranule or an ionic form (liposome) and / In the form of a non-ionic follicle dispersing agent, or in the form of creams, skins, lotions, powders, ointments, sprays or conical sticks. These compositions may be prepared according to conventional methods in the art.

When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.

In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.

When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .

When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.

In one embodiment of the present invention, the cosmetic composition may further contain an enhancer. The thickening agent included in the cosmetic composition of the present invention may be selected from the group consisting of methylcellulose, carboxymethylcellulose, carboxymethylhydroxyguanine, hydroxymethylcellulose, hydroxyethylcellulose, carboxyvinyl polymer, polyquaternium, cetearyl alcohol, Carrageenan, and the like. Among them, at least one of carboxymethyl cellulose, carboxyvinyl polymer, and polyquaternium can be used, and most preferably, it can be a carboxyvinyl polymer.

In one embodiment of the present invention, the cosmetic composition may contain various bases and additives as appropriate, and the kind and amount of these components can be easily selected by the inventors. The composition may contain an additive that is acceptable according to need, and may further include components such as preservatives, pigments, and additives customary in the art.

The preservative may specifically be phenoxyethanol or 1,2-hexanediol, and the perfume may be an artificial perfume or the like.

And, in one embodiment of the present invention, the cosmetic composition may comprise a composition selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides, sphingolipids and seaweed extracts. Examples of the compounding ingredients that may be added include organic solvents such as a preservative component, a moisturizer, an emollient, a surfactant, an organic and inorganic pigment, an organic powder, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a plant extract, a pH adjuster, A blood circulation promoter, a cold agent, a restriction agent, and purified water.

The components to be added in addition to these components are not limited thereto, and any of the above components can be compounded within a range that does not impair the objects and effects of the present invention.

Further, in the above aspect, the composition may be a health food composition. The formulation of the food composition according to one aspect of the present invention is not particularly limited, but may be formulated into, for example, tablets, granules, powders, liquid preparations such as drinks, caramels, gels, bars and the like. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.

In the food composition according to one aspect of the present invention, determination of the dosage of the active ingredient is within the level of those skilled in the art, and its daily dose is, for example, 0.1 mg / kg / day to 5000 mg / kg / May be 50 mg / kg / day to 500 mg / kg / day, but is not limited thereto, and may vary depending on various factors such as the age, health condition, and complications of the subject.

The food composition according to one aspect of the present invention can be used for various foods such as chewing gum, caramel product, candy, ice cream, confectionery, beverage such as soft drink, mineral water and alcoholic beverage, health including vitamins and minerals It may be a functional food.

In addition to the above, in one aspect of the present invention, the food composition includes flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.) Salts of alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In another aspect of the present invention, the functional food compositions may include natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the proportion of such additives is not so critical, in one aspect of the present invention, it is common to include 0 to about 20 parts by weight per 100 parts by weight of the composition.

Hereinafter, the present invention will be described in more detail with reference to the following examples and experimental examples. However, these examples and experimental examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited by the following examples.

[Example 1] Preparation of dermal papilla cells

Human dermal papilla cells (hDPs, C-12071) were purchased from Promocell (GmbH, Heidelberg, Germany). Human dermal papilla cells were cultured in a culture medium (Follicle Dermal Papilla Cell Growth Medium Kit (C-26502)) purchased from Promocells under the conditions of 37 ° C and 5% CO 2 in an incubator. The culture of dermal papilla cells was performed three times in total (Yoon SY et al., A role of placental growth factor in hair growth, Dermatol. Sci.

[Example 2] Confirmation of promoting effect of ginsenoside F5 on placental growth factor expression

3 × 10 4 subcultured dermal papilla cells obtained in Example 1 were dispensed into a 35 mm culture dish, and the materials expected to have hair loss improving effect (epigallocatechin (EGC), epigallocatechin gallate (EGCG) (GT stem cells), ginsenoside F1, ginsenoside F2, ginsenoside F5, and ginsenoside compound K were each treated at 10 ppm (w / w) for 24 hours , And the amount of placental growth factor expression was measured. The materials were purchased from Nanjing Chemlin Chemical Industry Co.

The expression level of placental growth factor (PIGF) was measured using an immunoenzymometric assay kit (Raybiotech, Cat. No. ELH-PLGF) according to the protocol of the kit manufacturer. Specifically, to prepare a standard curve, PIGF (1,000 pg / ml, 333.3 pg / ml, 111.1 pg / ml, 37.04 pg / ml, 12.35 pg / ml, 4.125 pg / pg / ml, 0 pg / ml) and the culture solution (200 ㎕) treated with the candidate substances were put in a 96-well plate coated with PIGF antibody. After washing three times with wash buffer, biotinylated anti-human PlGF antibody was added to each well and incubated for about 1 hour. Then, unbound biotinylated human PIGF antibody was washed and washed three times with wash buffer, HRP-conjugated streptavidin was added to each well, followed by incubation for 45 minutes. After 3 rinses with washing buffer, 3,3,5,5-tetramethylbenzidine (TMB) was added to wait for 30 minutes for color development, A stop solution was added to stop the chemical reaction of each well and then measured at 450 nm in a spectrophotometer. A standard curve is prepared based on the standard PIGF (standard PlGF) concentration value and the OD (optical density) value measured by the spectrophotometer, and the OD value of the sample subjected to each candidate substance is substituted. The amount of expression of the increased PlGF was calculated. As a result, it was found that when the ginsenoside F5 was treated, the expression level of PlGF was increased by 50% or more as compared with the negative control (Fig. 1).

Formulation examples of compositions according to one aspect of the present invention are described below, but may be applied to various other formulations, which are not intended to be limiting but merely illustrative of the present invention.

[Formulation Example 1] Soft capsule

A soft capsule filling liquid is prepared by mixing 0.004 mg of ginsenoside F5, 9 mg of vitamin E, 9 mg of vitamin C, 2 mg of palm oil, 8 mg of vegetable hardening oil, 4 mg of yellowing powder and 9 mg of lecithin and mixing them according to a conventional method. 400 mg per capsule is filled to prepare a soft capsule. Separately from this, a soft capsule sheet was prepared in a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerin and 10 parts by weight of sorbitol solution, and filled with the filling solution to prepare a soft capsule containing 400 mg of the composition according to an aspect of the present invention do.

[Formulation Example 2] Tablets

0.005 mg of the ginsenoside F5 of Example 1, 9 mg of vitamin E, 9 mg of vitamin C, 200 mg of galactooligosaccharide, 60 mg of lactose and 140 mg of maltose were mixed and granulated using a fluidized bed drier, and sugar ester 6 Mg. 500 mg of these compositions are tabletted by conventional methods to prepare tablets.

[Formulation Example 3] Health functional food

Health functional foods were prepared according to the compositions shown in Table 1 below by a conventional method.

Compounding ingredient content Ginsenoside F5 30 μg Vitamin A acetate 70 μg Vitamin E 1.0 mg Vitamin B1 0.13 mg Vitamin B2 0.15 mg Vitamin B6 0.5 mg Vitamin B12 0.2 μg Vitamin C 10 mg Biotin 10 μg Nicotinic acid amide 1.7 mg Folic acid 50 μg Calcium pantothenate 0.5 mg Ferrous sulfate 1.75 mg Zinc oxide 0.82 mg Magnesium carbonate 25.3 mg Potassium monophosphate 15 mg Dicalcium phosphate 55 mg Potassium citrate 90 mg Calcium carbonate 100 mg Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a component suitable for a health functional food as a preferred embodiment, the compounding ratio may be arbitrarily modified.

[Formulation Example 4] Health drinks

Health drinks were prepared in a conventional manner according to the composition shown in Table 2 below.

Compounding ingredient content Ginsenoside F5 200 mg Citric acid 1000 mg oligosaccharide 100 g Taurine 1g Purified water Balance

The above components are mixed according to a conventional health drink manufacturing method, and the mixture is stirred and heated at 85 DEG C for about 1 hour, and then the solution is sterilized by filtration.

[Formulation Example 5] Shampoo

Shampoos were prepared in a conventional manner according to the composition shown in Table 3 below.

Compounding ingredient Content (% by weight) Ginsenoside F5 0.001 Ammonium laureth sulfate 10.0 Glycol distearate 2.0 Cetyl alcohol 0.6 Cocamide MEA 0.5 Ammonium lauryl sulfate 6.0 Guar hydroxypropyltrimonium chloride 0.15 Polyquaternium-10 0.1 silicon 0.5 Distearyl chloride dimethyl ammonium chloride 0.2 Sodium coco amphoacetate 4.0 Spices 1.0 antiseptic 0.03 Citric acid Suitable amount Purified water Balance

[Formulation Example 6] Rinse

Rinse was prepared according to a conventional method according to the composition shown in Table 4 below.

Compounding ingredient Content (% by weight) Ginsenoside F5 0.001 Cetyl alcohol 3.0 Glycerin monostateate 1.0 Hydroxyethylcellulose 1.0 Propylene glycol 4.0 Methyl parahydroxybenzoate 0.2 Stearyldimethylbenzylammonium chloride 25% 10.0 Spices Suitable amount Pigment Suitable amount Citric acid Suitable amount Purified water Balance

[Formulation Example 7] ointment

Ointments were prepared in a conventional manner according to the compositions shown in Table 5 below.

Compounding ingredient Content (% by weight) Ginsenoside F5 0.001 Butylene glycol 4.0 Liquid paraffin 15.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / capric triglyceride 3.0 Squalane 1.0 Cetearyl glucoside 1.5 Sorbitan stearate 0.4 Cetearyl alcohol 1.0 Wax 4.0 glycerin 8.0 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 8] Massage cream

Massage creams were prepared in a conventional manner according to the compositions shown in Table 6 below.

Compounding ingredient Content (% by weight) Ginsenoside F5 0.001 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 45.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / capric triglyceride 3.0 Wax 4.0 Cetearyl glucoside 1.5 Sesquioleic acid sorbitan 0.9 Vaseline 3.0 paraffin 1.5 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 9]

A hair pack was prepared according to the conventional method according to the composition shown in Table 7 below.

Compounding ingredient Content (% by weight) Ginsenoside F5 0.001 glycerin 4.0 Polyvinyl alcohol 15.0 Hyaluronic acid extract 5.0 Beta Glucan 7.0 Allantoin 0.1 Nonyl phenyl ether 0.4 Polysorbate 60 1.2 Ethanol preservative 6.0 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 10]

Injections were prepared in a conventional manner according to the composition shown in Table 8 below.

Compounding ingredient content Ginsenoside F5 0.01-0.05 mg Sterile sterilized water for injection Suitable amount pH adjusting agent Suitable amount

While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (7)

A composition for preventing or improving hair loss, or promoting hair growth, comprising as an active ingredient ginsenoside F5, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof. The method according to claim 1,
Wherein said composition promotes secretion of growth factors of scalp cells. 3. The method of claim 2,
Wherein the scalp cell is a dermal papilla cell, the composition for preventing or improving hair loss, or for promoting hair growth. 3. The method of claim 2,
Wherein the growth factor is a placental growth factor, for preventing or ameliorating hair loss, or promoting hair growth. The method according to claim 1,
The ginsenoside F5 is derived from ginseng, and is used for preventing or ameliorating hair loss, or promoting hair growth. The method according to claim 1,
The ginsenoside F5,
(W / w) to 10% (w / w) based on the total weight of the composition. The method according to claim 1,
The composition may comprise,
A composition for the prevention or alleviation of hair loss, or for promoting hair growth, which is a pharmaceutical composition, a cosmetic composition or a health food composition.

Images